Edwards Announces Start Of U.S. Study Of Self-Expanding Transcatheter Heart Valve
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Canaccord Reiterates Buy on Edwards Lifesciences (EW); Sees Buying Opportunity
October 9, 2018 9:00 AM EDTCanaccord Genuity analyst, Jason Mills, reiterated a Buy rating and $177.00 price target on Edwards Lifesciences (NYSE: EW) following a recent pullback. Mills sees the recent weakness as a buying opportunity.
Mills thinks the post-COAPT readout for EW is extremely positive, especially given EW plans... More
